These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
112 related articles for article (PubMed ID: 13203743)
1. Cancer of the genitourinary tract. LEADBETTER WF N Engl J Med; 1954 Sep; 251(14):562-71; concl. PubMed ID: 13203743 [No Abstract] [Full Text] [Related]
2. The impact of pretreatment prostate volume on severe acute genitourinary toxicity in prostate cancer patients treated with intensity-modulated radiation therapy. Aizer AA; Anderson NS; Oh SC; Yu JB; McKeon AM; Decker RH; Peschel RE Int J Radiat Oncol Biol Phys; 2011 Feb; 79(2):379-84. PubMed ID: 20452135 [TBL] [Abstract][Full Text] [Related]
3. [Early diagnosis of urogenital tumors]. Harzmann R Z Hautkr; 1987 May; 62(9):665-76, 681-2. PubMed ID: 3617865 [TBL] [Abstract][Full Text] [Related]
4. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity. Brabbins D; Martinez A; Yan D; Lockman D; Wallace M; Gustafson G; Chen P; Vicini F; Wong J Int J Radiat Oncol Biol Phys; 2005 Feb; 61(2):400-8. PubMed ID: 15667959 [TBL] [Abstract][Full Text] [Related]
6. Inverse relationship between biochemical outcome and acute toxicity after image-guided radiotherapy for prostate cancer. Vesprini D; Catton C; Jacks L; Lockwood G; Rosewall T; Bayley A; Chung P; Gospodarowicz M; Ménard C; Milosevic M; Nichol A; Skala M; Warde P; Bristow RG Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):608-16. PubMed ID: 22099034 [TBL] [Abstract][Full Text] [Related]
7. Comparison of late gastrointestinal and genitourinary toxicity of prostate cancer patients undergoing intensity-modulated versus conventional radiotherapy using localized fields. Jani AB; Su A; Correa D; Gratzle J Prostate Cancer Prostatic Dis; 2007; 10(1):82-6. PubMed ID: 16983394 [TBL] [Abstract][Full Text] [Related]
8. Late gastrointestinal and urogenital side-effects after radiotherapy--incidence and prevalence. Subgroup-analysis within the prospective Austrian-German phase II multicenter trial for localized prostate cancer. Schmid MP; Pötter R; Bombosch V; Sljivic S; Kirisits C; Dörr W; Goldner G Radiother Oncol; 2012 Jul; 104(1):114-8. PubMed ID: 22727264 [TBL] [Abstract][Full Text] [Related]
9. Association of urethral toxicity with dose exposure in combined high-dose-rate brachytherapy and intensity-modulated radiation therapy in intermediate- and high-risk prostate cancer. Ghadjar P; Matzinger O; Isaak B; Behrensmeier F; Stroux A; Rentsch CA; Thalmann GN; Aebersold DM Radiother Oncol; 2009 May; 91(2):237-42. PubMed ID: 19167121 [TBL] [Abstract][Full Text] [Related]
10. Outcomes in men with large prostates (≥ 60 cm(3)) treated with definitive proton therapy for prostate cancer. McGee L; Mendenhall NP; Henderson RH; Morris CG; Nichols RC; Marcus RJ; Li Z; Mendenhall WM; Williams CR; Hoppe BS Acta Oncol; 2013 Apr; 52(3):470-6. PubMed ID: 23244673 [TBL] [Abstract][Full Text] [Related]
11. Isolated recurrence of ductal prostate cancer to anterior urethra. Green JM; Tang WW; Jensen BW; Orihuela E Urology; 2006 Aug; 68(2):428.e13-5. PubMed ID: 16904476 [TBL] [Abstract][Full Text] [Related]
12. Salvage hypofractionated radiotherapy for biochemically recurrent prostate cancer after radical prostatectomy. Wong GW; Palazzi-Churas KL; Jarrard DF; Paolone DR; Graf AK; Hedican SP; Wegenke JD; Ritter MA Int J Radiat Oncol Biol Phys; 2008 Feb; 70(2):449-55. PubMed ID: 17869014 [TBL] [Abstract][Full Text] [Related]
13. Toxicity after external beam radiotherapy for prostate cancer: an analysis of late morbidity in men with diabetes mellitus. Kalakota K; Liauw SL Urology; 2013 Jun; 81(6):1196-201. PubMed ID: 23540863 [TBL] [Abstract][Full Text] [Related]
14. Intensity-modulated radiotherapy reduces gastrointestinal toxicity in patients treated with androgen deprivation therapy for prostate cancer. Sharma NK; Li T; Chen DY; Pollack A; Horwitz EM; Buyyounouski MK Int J Radiat Oncol Biol Phys; 2011 Jun; 80(2):437-44. PubMed ID: 21050673 [TBL] [Abstract][Full Text] [Related]
15. Treatment results of PDR brachytherapy combined with external beam radiotherapy in 106 patients with intermediate- to high-risk prostate cancer. Pieters BR; Geijsen ED; Koedooder K; Blank LE; Rezaie E; van der Grient JN; de Reijke TM; Koning CC Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1037-42. PubMed ID: 20510545 [TBL] [Abstract][Full Text] [Related]
17. Acute and late toxicity in a randomized trial of conventional versus hypofractionated three-dimensional conformal radiotherapy for prostate cancer. Arcangeli G; Fowler J; Gomellini S; Arcangeli S; Saracino B; Petrongari MG; Benassi M; Strigari L Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1013-21. PubMed ID: 20447774 [TBL] [Abstract][Full Text] [Related]
18. A phase II study of external beam radiotherapy combined with permanent source brachytherapy for intermediate-risk, clinically localized adenocarcinoma of the prostate: preliminary results of RTOG P-0019. Lee WR; DeSilvio M; Lawton C; Gillin M; Morton G; Firat S; Baikadi M; Kuettel M; Greven K; Sandler H Int J Radiat Oncol Biol Phys; 2006 Mar; 64(3):804-9. PubMed ID: 16289906 [TBL] [Abstract][Full Text] [Related]
19. Whole pelvic radiotherapy versus prostate only radiotherapy in the management of locally advanced or aggressive prostate adenocarcinoma. Aizer AA; Yu JB; McKeon AM; Decker RH; Colberg JW; Peschel RE Int J Radiat Oncol Biol Phys; 2009 Dec; 75(5):1344-9. PubMed ID: 19464821 [TBL] [Abstract][Full Text] [Related]
20. Impact of hormone therapy on acute radiotherapy toxicity in the treatment of prostate cancer. Jani AB; Gratzle J; Myers M Prostate Cancer Prostatic Dis; 2005; 8(3):224-8. PubMed ID: 15983626 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]